258 related articles for article (PubMed ID: 23015417)
1. Epigenetic alterations in hematopoietic malignancies.
Chung YR; Schatoff E; Abdel-Wahab O
Int J Hematol; 2012 Oct; 96(4):413-27. PubMed ID: 23015417
[TBL] [Abstract][Full Text] [Related]
2. Alterations to
Venugopal K; Feng Y; Shabashvili D; Guryanova OA
Cancer Res; 2021 Jan; 81(2):254-263. PubMed ID: 33087320
[TBL] [Abstract][Full Text] [Related]
3. Impact of Histone Modifications and Their Therapeutic Targeting in Hematological Malignancies.
Markouli M; Strepkos D; Piperi C
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362442
[TBL] [Abstract][Full Text] [Related]
4. Emerging role of mutations in epigenetic regulators including MLL2 derived from The Cancer Genome Atlas for cervical cancer.
Li X
BMC Cancer; 2017 Apr; 17(1):252. PubMed ID: 28390392
[TBL] [Abstract][Full Text] [Related]
5. The landscape of alterations affecting epigenetic regulators in T-cell acute lymphoblastic leukemia: Roles in leukemogenesis and therapeutic opportunities.
Walia Y; de Bock CE; Huang Y
Int J Cancer; 2024 May; 154(9):1522-1536. PubMed ID: 38155420
[TBL] [Abstract][Full Text] [Related]
6. The Intersection of Epigenetic Alterations and Developmental State in Pediatric Ependymomas.
Kardian AS; Mack S
Dev Neurosci; 2024 Mar; ():. PubMed ID: 38527429
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic modifiers in normal and malignant hematopoiesis.
Haladyna JN; Yamauchi T; Neff T; Bernt KM
Epigenomics; 2015; 7(2):301-20. PubMed ID: 25942537
[TBL] [Abstract][Full Text] [Related]
8. Somatic alterations and dysregulation of epigenetic modifiers in cancers.
Aumann S; Abdel-Wahab O
Biochem Biophys Res Commun; 2014 Dec; 455(1-2):24-34. PubMed ID: 25111821
[TBL] [Abstract][Full Text] [Related]
9. The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes.
Huether R; Dong L; Chen X; Wu G; Parker M; Wei L; Ma J; Edmonson MN; Hedlund EK; Rusch MC; Shurtleff SA; Mulder HL; Boggs K; Vadordaria B; Cheng J; Yergeau D; Song G; Becksfort J; Lemmon G; Weber C; Cai Z; Dang J; Walsh M; Gedman AL; Faber Z; Easton J; Gruber T; Kriwacki RW; Partridge JF; Ding L; Wilson RK; Mardis ER; Mullighan CG; Gilbertson RJ; Baker SJ; Zambetti G; Ellison DW; Zhang J; Downing JR
Nat Commun; 2014 Apr; 5():3630. PubMed ID: 24710217
[TBL] [Abstract][Full Text] [Related]
10. Genomic and epigenomic co-evolution in follicular lymphomas.
Loeffler M; Kreuz M; Haake A; Hasenclever D; Trautmann H; Arnold C; Winter K; Koch K; Klapper W; Scholtysik R; Rosolowski M; Hoffmann S; Ammerpohl O; Szczepanowski M; Herrmann D; Küppers R; Pott C; Siebert R;
Leukemia; 2015 Feb; 29(2):456-63. PubMed ID: 25027518
[TBL] [Abstract][Full Text] [Related]
11. Driver mutations of cancer epigenomes.
Roy DM; Walsh LA; Chan TA
Protein Cell; 2014 Apr; 5(4):265-96. PubMed ID: 24622842
[TBL] [Abstract][Full Text] [Related]
12. Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.
Li H; Kaminski MS; Li Y; Yildiz M; Ouillette P; Jones S; Fox H; Jacobi K; Saiya-Cork K; Bixby D; Lebovic D; Roulston D; Shedden K; Sabel M; Marentette L; Cimmino V; Chang AE; Malek SN
Blood; 2014 Mar; 123(10):1487-98. PubMed ID: 24435047
[TBL] [Abstract][Full Text] [Related]
13. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia.
Gang EJ; Hsieh YT; Pham J; Zhao Y; Nguyen C; Huantes S; Park E; Naing K; Klemm L; Swaminathan S; Conway EM; Pelus LM; Crispino J; Mullighan CG; McMillan M; Müschen M; Kahn M; Kim YM
Oncogene; 2014 Apr; 33(17):2169-78. PubMed ID: 23728349
[TBL] [Abstract][Full Text] [Related]
14. MOZ regulates B-cell progenitors and, consequently, Moz haploinsufficiency dramatically retards MYC-induced lymphoma development.
Sheikh BN; Lee SC; El-Saafin F; Vanyai HK; Hu Y; Pang SH; Grabow S; Strasser A; Nutt SL; Alexander WS; Smyth GK; Voss AK; Thomas T
Blood; 2015 Mar; 125(12):1910-21. PubMed ID: 25605372
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathogenesis of follicular lymphoma.
Kishimoto W; Nishikori M
J Clin Exp Hematop; 2014; 54(1):23-30. PubMed ID: 24942943
[TBL] [Abstract][Full Text] [Related]
16. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance.
Easwaran H; Tsai HC; Baylin SB
Mol Cell; 2014 Jun; 54(5):716-27. PubMed ID: 24905005
[TBL] [Abstract][Full Text] [Related]
17. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission.
Corces-Zimmerman MR; Hong WJ; Weissman IL; Medeiros BC; Majeti R
Proc Natl Acad Sci U S A; 2014 Feb; 111(7):2548-53. PubMed ID: 24550281
[TBL] [Abstract][Full Text] [Related]
18. Polycomb repressive complex 2 (PRC2) suppresses Eμ-myc lymphoma.
Lee SC; Phipson B; Hyland CD; Leong HS; Allan RS; Lun A; Hilton DJ; Nutt SL; Blewitt ME; Smyth GK; Alexander WS; Majewski IJ
Blood; 2013 Oct; 122(15):2654-63. PubMed ID: 23982173
[TBL] [Abstract][Full Text] [Related]
19. The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion.
Lu C; Paschall AV; Shi H; Savage N; Waller JL; Sabbatini ME; Oberlies NH; Pearce C; Liu K
J Natl Cancer Inst; 2017 Jan; 109(6):. PubMed ID: 28131992
[TBL] [Abstract][Full Text] [Related]
20. Metformin and risk of hematological cancers in patients with diabetes: a systematic review and meta-analysis.
Wang M; Noghabaei G; Raeisi T; Li D; Alizadeh H; Alizadeh M
Ann Saudi Med; 2024; 44(2):126-134. PubMed ID: 38615182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
